Keywords: isis, pharmaceuticals, fails, crohn, disease, refocuses, been

Isis Pharmaceuticals' ISIS 2302 fails in Crohn's disease, refocuses R&D

Article | 16 December 1999

Print This

Isis Pharmaceuticals has been dealt a blow with the announcement ofnegative results from a trial of its antisense ICAM-1 inhibitor ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in